News - Patent Foramen Ovale
NMT Medical, Inc. (NASDAQ: NMTI) announced today that the Company has completed patient enrollment in its pivotal patent foramen ovale (PFO)/stroke clinical trial, CLOSURE I.
W. L. Gore & Associates (Gore) today announced that it has received approval from the US Food & Drug Administration (FDA) to proceed with the Gore REDUCE* Clinical Study.
NMT Medical, Inc. (NASDAQ: NMTI) today announced that the Company is closing down its patent foramen ovale (PFO)/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity.
Coherex Medical, Inc., a privately held medical device company, today announced it has successfully completed the first human cases of its Coherex FlatStent™ PFO Closure System. Under the direction of Professor Horst Sievert, M.D.
